Home
Clinical Trials
NCT04777357

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

380 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-28

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population.

Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites worldwide.

Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Bipolar I Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Depression RGH-188 Bipolar I Disorder Vraylar Cariprazine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cariprazine

Participants will receive flexible dose Cariprazine over a 6 week treatment period.

Group Type EXPERIMENTAL

Cariprazine

Intervention Type DRUG

Oral Capsule

Placebo

Participants will receive Placebo over a 6 week treatment period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral Capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cariprazine

Oral Capsule

Intervention Type DRUG

Placebo

Oral Capsule

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vraylar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) primary diagnosis of bipolar I disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL).
* Current depressive episode is more than 2 weeks and less than 12 months in duration.
* Participant has a lifetime history of at least one manic episode.
* Children's Depression Rating Scale - Revised (CDRS-R) score \> = 45 at Visit 1 and Visit 2.
* Young-Mania Rating Scale (YMRS) score \< = 12 with YMRS Item 1 (elevated mood) score \< = 2 at Visit 1 and Visit 2.
* Clinical Global Impression-Severity (CGI-S) scale score of \> = 4 (moderately ill) at Visit 1 and Visit 2.

Exclusion Criteria

* Participants with DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder.
* Participant has a history of meeting DSM-5 diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before Screening Visit 1.
* History of serotonin syndrome or neuroleptic malignant syndrome.
* Four or more episodes of a mood disturbance within the 12 months before Visit 1.
* DSM-5 diagnosis of intellectual disability (IQ \< 70), autism spectrum disorders, or documented history of chromosomal disorder with developmental impairment.
* History of seizures, with the exception of febrile seizures.
* Significant head trauma, history of tumor of the CNS, or any other condition that predisposes to seizures.
* Participant requires concomitant treatment with moderate or strong CYP3A4 inhibitors or with any CYP3A4 inducers.
* Participant requires concomitant treatment with any prohibited medication, supplement, or herbal product, including any psychotropic drug or any drug with psychotropic activity or with a potentially psychotropic component.
* Use of a depot antipsychotic within 2 cycles of their respective dosing interval prior to Screening Visit 1.
* Treatment with clozapine in a dose of \>= 50 mg/d in the past 2 years.
* History of or any current ocular disease including, but not limited to, retinal detachment, intraocular surgery, laser treatment, glaucoma, cataracts, or clinically significant ocular trauma (with the exception of refractive errors).

Minimum Eligible Age

10 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pillar Clinical Research /ID# 226504

Bentonville, Arkansas, United States

Site Status COMPLETED

Advanced Research Center /ID# 227073

Anaheim, California, United States

Site Status RECRUITING

Care Access Research /ID# 226316

Beverly Hills, California, United States

Site Status COMPLETED

ProScience Research Group /ID# 226223

Culver City, California, United States

Site Status COMPLETED

National Institute of Clinical Research - Garden Grove /ID# 262835

Garden Grove, California, United States

Site Status COMPLETED

Duplicate_Alliance for Research - Long Beach /ID# 226522

Long Beach, California, United States

Site Status COMPLETED

CHOC Children's Hospital /ID# 260298

Orange, California, United States

Site Status RECRUITING

ATP Clinical Research- Orange /ID# 253719

Orange, California, United States

Site Status RECRUITING

Prospective Research Innovations Inc /ID# 240774

Rancho Cucamonga, California, United States

Site Status COMPLETED

Inland Psychiatric Medical Group /ID# 274621

Redlands, California, United States

Site Status RECRUITING

University of California Davis Health /ID# 268306

Sacramento, California, United States

Site Status RECRUITING

University of California, San Diego Department of Psychiatry /ID# 226463

San Diego, California, United States

Site Status COMPLETED

Lumos Clinical Research Center /ID# 262805

San Jose, California, United States

Site Status RECRUITING

Pacific Clinical Research Management Group /ID# 227075

Upland, California, United States

Site Status COMPLETED

D&H Doral Research Center-Doral /ID# 255458

Doral, Florida, United States

Site Status RECRUITING

Advanced Research Institute of Miami /ID# 228222

Homestead, Florida, United States

Site Status RECRUITING

Columbus Clinical Services, Llc /Id# 229792

Miami, Florida, United States

Site Status COMPLETED

G+C Research Group, LLC /ID# 261399

Miami, Florida, United States

Site Status RECRUITING

Florida Research Center, Inc. /ID# 240775

Miami, Florida, United States

Site Status RECRUITING

South Florida Research Ph I-IV /ID# 240778

Miami Springs, Florida, United States

Site Status COMPLETED

Medical Research Group of Central Florida /ID# 256757

Orange City, Florida, United States

Site Status RECRUITING

APG Research, LLC /ID# 226519

Orlando, Florida, United States

Site Status RECRUITING

Nova Psychiatry Inc. /ID# 270892

Orlando, Florida, United States

Site Status RECRUITING

Panhandle Research and Medical Clinic, LLC /ID# 268522

Pensacola, Florida, United States

Site Status RECRUITING

D&H Tamarac Research Center /ID# 250434

Tamarac, Florida, United States

Site Status RECRUITING

University of South Florida- Neuroscience Institute /ID# 246508

Tampa, Florida, United States

Site Status COMPLETED

Atlanta Center for Medical Research /ID# 226480

Atlanta, Georgia, United States

Site Status COMPLETED

CenExcel iResearch LLC /ID# 228695

Decatur, Georgia, United States

Site Status RECRUITING

Atlanta Behavioral Research, LLC /ID# 226486

Dunwoody, Georgia, United States

Site Status RECRUITING

Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 226371

Stockbridge, Georgia, United States

Site Status COMPLETED

Duplicate_Ascension St. Elizabeth /ID# 240772

Chicago, Illinois, United States

Site Status COMPLETED

Baber Research Group /ID# 232279

Naperville, Illinois, United States

Site Status COMPLETED

Advanced Quality Medical Research /ID# 272902

Orland Park, Illinois, United States

Site Status RECRUITING

Indiana University /ID# 260705

Indianapolis, Indiana, United States

Site Status RECRUITING

Benchmark Research /ID# 260714

Shreveport, Louisiana, United States

Site Status RECRUITING

The Kennedy Krieger Institute /ID# 226509

Baltimore, Maryland, United States

Site Status RECRUITING

Med Clinical Research Partners LLC /ID# 240773

Irvington, New Jersey, United States

Site Status RECRUITING

Duplicate_NeuroCognitive and Behavioral Institute, Inc /ID# 227077

Mount Arlington, New Jersey, United States

Site Status COMPLETED

UB Department of Psychiatry /ID# 226373

Buffalo, New York, United States

Site Status COMPLETED

New Dawn Psychiatric Services PLLC /ID# 229782

Kinston, North Carolina, United States

Site Status COMPLETED

Quest Therapeutics of Avon Lake /ID# 226349

Avon Lake, Ohio, United States

Site Status COMPLETED

University of Cincinnati /ID# 226465

Cincinnati, Ohio, United States

Site Status COMPLETED